U.S. markets open in 8 hours 11 minutes
  • S&P Futures

    3,886.75
    -12.00 (-0.31%)
     
  • Dow Futures

    31,430.00
    -79.00 (-0.25%)
     
  • Nasdaq Futures

    13,248.00
    -31.75 (-0.24%)
     
  • Russell 2000 Futures

    2,260.80
    -14.00 (-0.62%)
     
  • Crude Oil

    59.90
    -0.74 (-1.22%)
     
  • Gold

    1,714.20
    -8.80 (-0.51%)
     
  • Silver

    26.11
    -0.56 (-2.11%)
     
  • EUR/USD

    1.2029
    -0.0030 (-0.25%)
     
  • 10-Yr Bond

    1.4460
    0.0000 (0.00%)
     
  • Vix

    23.35
    -4.60 (-16.46%)
     
  • GBP/USD

    1.3894
    -0.0027 (-0.19%)
     
  • USD/JPY

    106.8220
    +0.0920 (+0.09%)
     
  • BTC-USD

    48,583.90
    +2,187.70 (+4.72%)
     
  • CMC Crypto 200

    973.59
    -13.06 (-1.32%)
     
  • FTSE 100

    6,588.53
    +105.10 (+1.62%)
     
  • Nikkei 225

    29,428.46
    -235.04 (-0.79%)
     

Auris Medical Holding to Present at the 13th Annual LD Micro Main Event Conference

  • Oops!
    Something went wrong.
    Please try again later.
Auris Medical AG
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Hamilton, Bermuda, December 7, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced that Chairman and CEO Thomas Meyer will present at the 13th Annual LD Micro Main Event investor conference on Tuesday, December 15, 2020, at 10:40 a.m. EST. The event will be webcast live and available via the event homepage https://ve.mysequire.com/.

About Auris Medical

Auris Medical is a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders. The Company is focused on the development of intranasal betahistine for the treatment of vertigo (AM-125, in Phase 2) and for the prevention of antipsychotic-induced weight gain and somnolence (AM-201, post Phase 1b). Through its affiliate Altamira Medica, the Company is developing a nasal spray for protection against airborne pathogens and allergens (AM-301). In addition, Auris Medical has two Phase 3 programs under development: Sonsuvi® (AM-111) for acute inner ear hearing loss and Keyzilen® (AM-101) for acute inner ear tinnitus. The Company was founded in 2003 and is headquartered in Hamilton, Bermuda with its main operations in Basel, Switzerland. The shares of Auris Medical Holding Ltd. trade on the NASDAQ Capital Market under the symbol “EARS.”

Investor contact:

investors@aurismedical.com